|
|
|
28 Jun 2006 |
Insmed Presents Positive IPLEX(TM) Data At ENDO 2006
|
|
27 Jun 2006 |
Presentations of ConjuChem's Novel Growth Hormone Therapeutic Highlighted at the 88th Annual Meeting of the Endocrine Society
|
|
27 Jun 2006 |
Nastech Pharmaceutical Company Inc. Enters into Development and License Agreement With Amylin Pharmaceuticals, Inc.
|
|
27 Jun 2006 |
Nastech's Parathyroid Hormone (PTH1-34) Nasal Spray Demonstrated Similar Exposure Levels to Approved Injectable Product in Phase I Study in the Elderly
|
|
27 Jun 2006 |
Wythe Therapeutics and VeroScience Announce Worldwide License for Cycloset(R)
|
|
27 Jun 2006 |
Metabolex Enters Into A Comprehensive Development And Commercialization Agreement With Ortho-Mcneil, Inc. For Drugs For Metabolic Diseases
|
|
26 Jun 2006 |
Ligand Earns Milestone as Wyeth Submits NDA for Bazedoxifene for Osteoporosis
|
|
26 Jun 2006 |
IND Lodged with FDA for Clinical Trial of VivaGel for Genital Herpes
|
|
24 Jun 2006 |
Altus Pharmaceuticals Announces Positive Results from Phase II Study in Growth Hormone Deficient Patients with Once-per-Week Growth Hormone
|
|
23 Jun 2006 |
Indevus Completes Enrollment in Pharmacokinetic Trial for NEBIDO(R)
|
|
23 Jun 2006 |
Savient's Puricase(R) (PEG-uricase) Phase 2 Results Show Powerful Anti-hyperuricemic Activity in Treatment-Failure Gout Patients
|
|
22 Jun 2006 |
ACOMPLIA(R) (rimonabant) receives marketing authorisation in the European Union
|
|
22 Jun 2006 |
Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss
|
|
21 Jun 2006 |
ConjuChem Successfully Completes Patient Enrollment of its Phase II Trial of DAC(TM):GRF for Treatment of HIV Lipodystrophy
|
|
20 Jun 2006 |
Niaspan(R) Combined with Low/Moderate Dosed Statin Achieves Better Total Lipid Control vs. Higher Dose Statin Monotherapy or Zocor(R)/Zetia(R)
|
|
20 Jun 2006 |
Cytokinetics Announces the Extension of Research Collaboration with GlaxoSmithKline
|
|
19 Jun 2006 |
Biggest LDL-C Reduction Ever Shown In Patients Is Achieved With A CRESTOR Combination Therapy
|
|
19 Jun 2006 |
New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly More Effective than Crestor(R) (rosuvastatin) at Lowering LDL ''Bad'' Cholesterol At All Doses Compared
|
|
15 Jun 2006 |
Auxilium Pharmaceuticals Announces Top-Line Results From Phase IV Trial of Testim(R) in Patients With Type II Diabetes
|
|
15 Jun 2006 |
Savient Pharmaceuticals Initiates Patient Dosing for Puricase(R) Phase 3 Clinical Study; Company on track for BLA filing in late 2007
|
|
14 Jun 2006 |
Pfizer Signs Agreement with Bayer to License Compounds for Potential Treatment of Obesity, Diabetes and Related Disorders
|
|
14 Jun 2006 |
ConjuChem's PC-DAC(TM):Exendin-4 presented at the American Diabetes Association annual meeting
|
|
14 Jun 2006 |
CeraPedics Announces Results of P-15(TM) Non-Union/Delayed Union Pilot Study Published in International Orthopaedics
|
|
13 Jun 2006 |
Novartis Unveils Further Impressive Efficacy Data for Galvus(R), an Investigational Oral Diabetes Compound, Showing Significant Blood Sugar Reductions
|
|
13 Jun 2006 |
Study of over 10,000 patients indicates that Levemir® effectively treats diabetes safely and without causing weight gain
|
|
13 Jun 2006 |
Liraglutide Phase 2 Study Shows Increased Insulin Secretion and Improved Blood Glucose Control in People with Type 2 Diabetes
|
|
13 Jun 2006 |
Isis Pharmaceuticals Reports Positive Phase 2 Data: ISIS 113715 Improves Glucose Control in Patients With Type 2 Diabetes
|
|
13 Jun 2006 |
Forbes Medi-Tech Announces Completion of Enrollment for FM-VP4 US Phase II Trial
|
|
13 Jun 2006 |
OSI Pharmaceuticals Presents Positive Results from Phase IIa Clinical Trial of Its DPIV Inhibitor, PSN9301, at Annual Meeting of American Diabetes Association
|
|
13 Jun 2006 |
Arena Pharmaceuticals' Lorcaserin Hydrochloride Phase 2b Study Results Demonstrate Significant Weight Loss and Positive Effect on BMI and Waist and Hip Circumference in Obese Patients
|
|
13 Jun 2006 |
Multiple Second-Generation Antisense Drugs Show Potential as New Treatments for Metabolic Disorders
|
|
13 Jun 2006 |
Oramed Pharmaceuticals Combats Diabetes with Oral Insulin
|
|
12 Jun 2006 |
Data Presented at American Diabetes Association Annual Meeting Suggest Testosterone Levels Correlate with Insulin Resistance and Insulin Sensitivity in Type 2 Diabetes Patients
|
|
12 Jun 2006 |
Point Therapeutics' Diabetes Program Presented at American Diabetes Association 66th Annual Scientific Sessions; Chronic Administration of PT-630 Results in Triglyceride Reduction and other Anti-Diabetes Activities
|
|
12 Jun 2006 |
CombinatoRx Presents Preclinical Data on CRx-401, a Novel Insulin Sensitizer with Anti-Diabetic Activity
|
|
12 Jun 2006 |
Metabasis Therapeutics Comments On Clinical Results On CS-917 Presented At American Diabetes Association Meeting
|
|
12 Jun 2006 |
Novocell Presents Phase I/II Data on Safety and Response to Encapsulated Islets at the American Diabetes Association's 66th Annual Scientific Session
|
|
12 Jun 2006 |
Targeting MicroRNAs With Antisense Drugs Produces Compelling Preclinical Data in Animal Studies
|
|
11 Jun 2006 |
Data on AIR Inhaled Insulin System Presented at American Diabetes Association Meeting
|
|
11 Jun 2006 |
Metabolex Initiates Phase 2/3 Trial of Metaglidasen in Patients With Type 2 Diabetes
|
|
11 Jun 2006 |
FDA Approves New Indication for ZETIA® (ezetimibe) - Merck/Schering-Plough's Cholesterol Lowering Drug - for Administration in Combination with Fenofibrate, Along with Diet
|
|
11 Jun 2006 |
BYETTA(R) Shown to Reduce Blood Glucose Levels When Added to Patients Using a TZD
|
|
11 Jun 2006 |
Late Breaking Data at ADA 2006 Shows Amylin-Leptin Co-Administration Reduces Body Weight and Body Fat in Animal Studies
|
|
11 Jun 2006 |
BYETTA(R) Extension Study Shows Sustained Improvements in Blood Glucose Control and Progressive Weight Loss After Two Years
|
|
11 Jun 2006 |
Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes
|
|
11 Jun 2006 |
OREXIGEN(TM) Therapeutics Reports Positive Phase II Results for Contrave(TM) Combination-Therapy to Treat Obesity
|
|
11 Jun 2006 |
First Clinical Trial to Demonstrate Colesevelam HCl Plus Stable Oral Antidiabetic Medication Improves Glycemic Control in Patients With Type 2 Diabetes
|
|
11 Jun 2006 |
New Data Demonstrate Benefits of Initial Use of Avandaryl(R) (Rosiglitazone Maleate and Glimepiride) in People With Type 2 Diabetes
|
|
11 Jun 2006 |
ACTOS(R) (pioglitazone HCl) to Be Studied in New Trial Investigating Its Effects on Atherosclerosis in Patients With Type 2 Diabetes
|
|
11 Jun 2006 |
Newly Released Phase III Studies for JANUVIA(TM), Merck's Investigational Once-Daily Medicine for Type 2 Diabetes, Showed Significantly Reduced Blood Sugar Levels When Used as Monotherapy or as Add-On Treatment
|
| |
|
Results 901 - 950 of 1094 |
